Cite
Empagliflozin Ameliorates Obesity-Related Cardiac Dysfunction by Regulating Sestrin2-Mediated AMPK-mTOR Signaling and Redox Homeostasis in High-Fat Diet-Induced Obese Mice.
MLA
Sun, Xiaodong, et al. “Empagliflozin Ameliorates Obesity-Related Cardiac Dysfunction by Regulating Sestrin2-Mediated AMPK-MTOR Signaling and Redox Homeostasis in High-Fat Diet-Induced Obese Mice.” Diabetes, vol. 69, no. 6, June 2020, pp. 1292–305. EBSCOhost, https://doi.org/10.2337/db19-0991.
APA
Sun, X., Han, F., Lu, Q., Li, X., Ren, D., Zhang, J., Han, Y., Xiang, Y. K., & Li, J. (2020). Empagliflozin Ameliorates Obesity-Related Cardiac Dysfunction by Regulating Sestrin2-Mediated AMPK-mTOR Signaling and Redox Homeostasis in High-Fat Diet-Induced Obese Mice. Diabetes, 69(6), 1292–1305. https://doi.org/10.2337/db19-0991
Chicago
Sun, Xiaodong, Fang Han, Qingguo Lu, Xuan Li, Di Ren, Jingwen Zhang, Ying Han, Yang K. Xiang, and Ji Li. 2020. “Empagliflozin Ameliorates Obesity-Related Cardiac Dysfunction by Regulating Sestrin2-Mediated AMPK-MTOR Signaling and Redox Homeostasis in High-Fat Diet-Induced Obese Mice.” Diabetes 69 (6): 1292–1305. doi:10.2337/db19-0991.